OncoCyte EBITDA Margin 2014-2025 | OCX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

OncoCyte ebitda margin from 2014 to 2025. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

OncoCyte EBITDA Margin 2014-2025 | OCX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

OncoCyte ebitda margin from 2014 to 2025. Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.

Related Stocks
Company Name	Market Cap
Danaher (DHR)	$133.5B
Elevance Health (ELV)	$96.1B
CVS Health (CVS)	$84.8B
Cencora (COR)	$55.6B
DiDi Global (DIDIY)	$20.3B
Natera (NTRA)	$20B
BioMerieux (BMXMF)	$15.6B
Solventum (SOLV)	$11.5B
ICON (ICLR)	$11.3B
EUROFINS SCIENT (ERFSF)	$11.1B
Revvity (RVTY)	$11B
CochLear (CHEOY)	$10.9B
Avantor (AVTR)	$10.3B
Doximity (DOCS)	$9.9B
Viatris (VTRS)	$9B
Medpace Holdings (MEDP)	$9B
Sonic Healthcare (SKHHY)	$7.7B
HealthEquity (HQY)	$7.3B
Charles River Laboratories (CRL)	$5.2B
Amplifon S.p.A (AMFPF)	$4.3B
Bausch + Lomb (BLCO)	$4.3B
Alignment Healthcare (ALHC)	$3.5B
Sotera Health (SHC)	$3B
BrightSpring Health Services (BTSG)	$2.9B
Organon (OGN)	$2.9B
Surgery Partners (SGRY)	$2.7B
GeneDx Holdings (WGS)	$2.7B
Concentras Parent (CON)	$2.6B
Progyny (PGNY)	$1.8B
Ardent Health Partners (ARDT)	$1.8B